[Stock idea]: Alivus Life Sciences – This API company just hit its highest-ever margins — here’s what management said 👇
Alivus is executing well on the things it controls — margins, cash generation, and non-GPL growth. The CDMO recovery in Q3 was the key positive surprise. The stock’s longer-term re-rating will hinge on how quickly the high-potency API pipeline and Solapur ramp up. Management is conservative but credible. Here are the key takeaways, But, before that: Help us grow: If you think our stock recommendations could add value to your friends, relatives, or acquaintances, we’d appreciate you spreading the word about Katalyst…
